Pharmaceutical composition

WO2024237309A1PCT designated stage expired Publication Date: 2024-11-21DAIICHI SANKYO HEALTHCARE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018136
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-16
Publication Date
2024-11-21

Smart Images

  • Figure JP2024018136_21112024_PF_FP_ABST
    Figure JP2024018136_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing a novel technology in which loxoprofen and / or a salt thereof are used to prevent pharyngitis and recover a water-swallowing reflex. The present invention provides a pharmaceutical composition which has a pharyngitis inhibitory action and which includes at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical Composition

[0001] The present invention relates to a pharmaceutical composition containing at least one selected from the group consisting of loxoprofen, its salts, and hydrates thereof. More specifically, the present invention relates to a pharmaceutical composition containing loxoprofen and / or its salts, which is suitable for suppressing pharyngitis.

[0002] Loxoprofen, a propionic acid-based nonsteroidal antipyretic, analgesic, and anti-inflammatory drug (hereinafter referred to as NSAIDs), is known to have potent antipyretic, analgesic, and anti-inflammatory effects, although it exhibits the same inhibitory effect on prostaglandin biosynthesis as other NSAIDs. Loxoprofen is a prodrug that is absorbed from the gastrointestinal tract as an unchanged form with weak gastric mucosal irritation after oral administration and becomes an active form in the body, and is therefore known to have the characteristic of causing less gastric mucosal damage than other NSAIDs (see, for example, Non-Patent Document 1).

[0003] Loxoprofen and / or its salts exhibit anti-inflammatory effects by inhibiting cyclooxygenase and are used as a symptomatic treatment for pharyngitis (see, for example, Patent Document 1). However, the details of the mechanism of action of loxoprofen and / or its salts on pharyngitis are not fully known.

[0004] JP 2001-10977

[0005] Pharmacology and Therapy Vol. 16 No. 2 1988 pp. 611-619

[0006] That is, the present invention provides a novel technique for suppressing pharyngitis and restoring the water swallowing reflex by using loxoprofen and / or a salt thereof.

[0007] The aspects of the present invention are as follows: <1> A pharmaceutical composition comprising at least one selected from the group consisting of loxoprofen, its salts, and hydrates thereof, and having an inhibitory effect on pharyngitis. <2> The pharmaceutical composition according to <1>, which has an effect of restoring the water swallowing reflex. <3> The pharmaceutical composition according to <1> or <2>, which has an effect of inhibiting swelling of the lamina propria mucosa. <4> The pharmaceutical composition according to any one of <1> to <3>, which has an effect of regenerating the mucosal epithelium. <5> The pharmaceutical composition according to any one of <1> to <4>, in which the content of the at least one selected from the group consisting of loxoprofen, its salts, and hydrates thereof or the salt thereof in the pharmaceutical composition is 5 to 30% by mass. <6> The pharmaceutical composition according to any one of <1> to <5>, in which the amount of the at least one selected from the group consisting of loxoprofen, its salts, and hydrates thereof or the salt thereof in a daily dose is 10 to 180 mg in terms of the anhydrous amount. <7> The pharmaceutical composition according to any one of <1> to <6>, which is in the form of a solid preparation or a liquid. <8> The pharmaceutical composition according to any one of <1> to <6>, which is in the form of an oral liquid, an oral liquid, an oral spray, or a mouthwash. <9> The pharmaceutical composition according to any one of <1> to <7>, which is an oral pharmaceutical composition. <10> The pharmaceutical composition according to <1> to <7>, which further comprises at least one selected from the group consisting of antacids, caffeines, sedatives, herbal medicines, antitussives / expectorants, antihistamines, anti-inflammatory agents, anticholinergics, and vitamins. <11> The pharmaceutical composition according to any one of <1> to <9>, which is used as an antipyretic analgesic or cold medicine. <12> The pharmaceutical composition according to any one of <1> to <7>, <9> and <10>, wherein the dosage form is a solid formulation, and the dosage form of the solid formulation is a tablet, fine granules, granules, or capsule.

[0008] The pharmaceutical composition of the present invention has an excellent effect of suppressing pharyngitis and can restore the water swallowing reflex function.

[0009] Figure 1 shows an outline of the method for preparing a pharyngitis model rat. Figure 2 shows an outline of the experimental method for measuring the water swallowing reflex. Figure 3 shows an outline of the experimental method for tissue analysis. Figure 4 shows the results of measuring the water swallowing reflex. Figure 5 shows the results of measuring the water swallowing reflex when loxoprofen was administered. Figure 6 shows the results of tissue analysis.

[0010] The pharmaceutical composition of the present invention contains at least one selected from the group consisting of loxoprofen, its salts, and hydrates thereof, and has an effect of suppressing pharyngitis. The pharmaceutical composition of the present invention also has an effect of restoring the water swallowing reflex. The pharmaceutical composition of the present invention also has an effect of suppressing swelling of the lamina propria mucosa.

[0011] The pharmaceutical composition of the present invention has the effect of suppressing swelling of the lamina propria of the mucosa. The pharmaceutical composition of the present invention has the effect of regenerating the mucosal epithelium.

[0012] The pharmaceutical composition of the present invention contains loxoprofen and / or a salt thereof. In the present invention, "loxoprofen and / or a salt thereof" means "at least one selected from the group consisting of loxoprofen, its salt, and hydrates thereof," and is loxoprofen or a salt thereof (including a hydrate salt) (the salt is preferably a pharmacologically acceptable salt), preferably loxoprofen sodium, and more preferably loxoprofen sodium dihydrate. Loxoprofen or a salt thereof used in the present invention is listed in the 18th Edition of the Japanese Pharmacopoeia as loxoprofen sodium hydrate.

[0013] First Embodiment The content of loxoprofen or a salt thereof in the pharmaceutical composition according to the first embodiment of the present invention is not limited, but is preferably 10 to 180 mg, more preferably 30 to 120 mg, and even more preferably 30 to 90 mg, in anhydrous form per dosage unit (single dose) for adults, and is administered 1 to 3 times per day. In the daily dose, the amount of loxoprofen or a salt thereof is preferably 10 to 180 mg, but may be 30 to 120 mg or 30 to 90 mg, in anhydrous form.

[0014] When the pharmaceutical composition of the present invention is in the form of a tablet, the content of loxoprofen or a salt thereof contained in the granulated granules in the tablet is not particularly limited, but the amount of the ingredient contained in the tablet per dosage unit (single dose) for adults is preferably 10 to 180 mg, more preferably 30 to 120 mg, even more preferably 30 to 90 mg, or may be 45 to 90 mg, in anhydrous equivalent, and in this case too, the number of doses is 1 to 3 times a day.

[0015] The amount of loxoprofen or a salt thereof contained in the pharmaceutical composition is not particularly limited, but may be 1 to 80% by mass, preferably 2 to 50% by mass, more preferably 5 to 30% by mass, or may be 5 to 20% by mass, based on the mass of the entire pharmaceutical composition.

[0016] <Antacid> In the present embodiment, the pharmaceutical composition may preferably further contain an antacid from the viewpoint of suppressing gastric mucosal damage. Examples of the antacid include alkaline earth metal and / or earth metal basic inorganic compounds, such as magnesium oxide, magnesium silicate, magnesium aluminosilicate, magnesium aluminum silicate, magnesium hydroxide, a co-precipitation product of magnesium hydroxide and aluminum potassium sulfate, magnesium carbonate, synthetic hydrotalcite, magnesium aluminometasilicate, dried aluminum hydroxide gel, synthetic aluminum silicate, magnesium alumina hydroxide, aluminum hydroxide gel, a co-precipitation product of aluminum hydroxide and sodium bicarbonate, a mixed dried gel of aluminum hydroxide and magnesium carbonate, and a co-precipitation product of aluminum hydroxide, magnesium carbonate, and calcium carbonate. Examples of alkali metal basic inorganic compounds include inorganic salts of metals selected from magnesium, aluminum, and calcium, such as bentonite, calcium silicate, calcium carbonate, precipitated calcium carbonate, calcium hydrogen phosphate, and anhydrous calcium hydrogen phosphate; examples of alkali metal basic inorganic compounds include inorganic salts of metals selected from sodium and potassium, such as dry sodium carbonate, sodium hydroxide, sodium bicarbonate, sodium carbonate hydrate, sodium hydrogen phosphate hydrate, anhydrous sodium monohydrogen phosphate, potassium hydroxide, potassium bicarbonate, and potassium carbonate; and other compounds include borax and glycine, and one or more components selected from these may be blended. Among these, one or more components selected from the group consisting of magnesium oxide, magnesium aluminometasilicate, aluminum hydroxide gel, and glycine are preferred.

[0017] When magnesium aluminometasilicate is used in the present invention, it may be one listed in the 18th Edition of the Japanese Pharmacopoeia or one listed in the Dictionary of Pharmaceutical Additives, and is readily available. Commercially available magnesium aluminometasilicate is not particularly limited, but an example is Neusilin manufactured by Fuji Chemical Industry Co., Ltd. The content of magnesium aluminometasilicate in the pharmaceutical composition of the present invention may be selected taking into consideration the disintegration property of the pharmaceutical composition, the dissolution property of the drug, and its function as an antacid, and is not particularly limited, but may be 0.1 to 90% by mass, 1 to 90% by mass, and preferably 5 to 80% by mass, based on the mass of the entire pharmaceutical composition.

[0018] When magnesium oxide is used in the present invention, magnesium oxide listed in the 18th Edition of the Japanese Pharmacopoeia or magnesium oxide listed in the Dictionary of Pharmaceutical Additives may be used, and these are readily available. Commercially available magnesium oxide is not particularly limited, but examples include magnesium oxide (light grade) manufactured by Tomita Pharmaceutical Co., Ltd. and magnesium oxide (heavy grade) manufactured by Kyowa Chemical Industry Co., Ltd. The content of magnesium oxide in the pharmaceutical composition of the present invention may be selected taking into consideration the disintegration property of the pharmaceutical composition, the drug dissolution property, and the function as an antacid, and is not particularly limited, but may be 0.1 to 90% by mass, 1 to 90% by mass, and preferably 5 to 80% by mass, based on the total mass of the pharmaceutical composition.

[0019] When an aluminum hydroxide gel is used in the present invention, it may be one listed as a dried aluminum hydroxide gel in the 18th Edition of the Japanese Pharmacopoeia, or one listed in the Dictionary of Pharmaceutical Additives, and these are readily available. Commercially available aluminum hydroxide gels are not particularly limited, but examples include dried aluminum hydroxide gel (S-100 grade) manufactured by Kyowa Chemical Industry Co., Ltd., dried aluminum hydroxide gel (fine granule grade) manufactured by Kyowa Chemical Industry Co., Ltd., and dried aluminum hydroxide gel (FM grade) manufactured by Kyowa Chemical Industry Co., Ltd. The content of aluminum hydroxide gel in the pharmaceutical composition of the present invention may be selected taking into consideration the disintegration property of the pharmaceutical composition, the drug dissolution property, and its function as an antacid, and is not particularly limited, but may be 0.1 to 90% by mass, 1 to 90% by mass, and preferably 5 to 80% by mass, based on the total mass of the pharmaceutical composition.

[0020] When glycine is used in the present invention, glycine listed in the 18th edition of the Japanese Pharmacopoeia may be used and is readily available. Commercially available glycine is not particularly limited, but examples include glycine manufactured by Organic Synthetic Chemicals Co., Ltd., glycine "for manufacturing use only" manufactured by Fujifilm Wako Pure Chemical Corporation, glycine manufactured by Ajinomoto Healthy Supply Co., Ltd., glycine (crystals) manufactured by Merck Ltd., and glycine (granules) manufactured by Merck Ltd. Commercially available glycine may also be crushed as appropriate before use. The content of glycine in the pharmaceutical composition of the present invention may be selected taking into consideration the disintegration property of the pharmaceutical composition, the drug dissolution property, and its function as an antacid, and is not particularly limited, but may be 0.1 to 90% by mass, 1 to 90% by mass, and preferably 5 to 80% by mass, based on the total mass of the pharmaceutical composition.

[0021] The pharmaceutical composition of the present invention may preferably further contain one or more caffeines selected from the group consisting of caffeines and sedatives. Examples of caffeines include caffeine hydrate, anhydrous caffeine, caffeine sodium benzoate, and caffeine citrate. The content of caffeines in the pharmaceutical composition of the present invention is not particularly limited, and may be, for example, 1 to 80% by mass, 3 to 80% by mass, or 5 to 70% by mass based on the mass of the entire pharmaceutical composition.

[0022] Examples of sedatives include allylisopropylacetylurea, bromovalerylurea, etc. The content of the sedative in the pharmaceutical composition of the present invention is not particularly limited, and may be, for example, 1 to 80% by mass, 2 to 80% by mass, or 2 to 70% by mass based on the mass of the entire pharmaceutical composition.

[0023] The pharmaceutical composition of the present invention may preferably further contain a compound having an amino group. The compound having an amino group is not particularly limited as long as it is a compound having an amino group, and may include, for example, one or more components selected from amino acids such as isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, histidine, tyrosine, cysteine, aspartic acid, asparagine, serine, glutamic acid, glutamine, proline, glycine, alanine, and arginine, carbocysteine, and tranexamic acid or a salt thereof. The amount of the compound having an amino group contained in the pharmaceutical composition is not particularly limited, and may be 1 to 90% by mass, 2 to 80% by mass, or 5 to 60% by mass based on the mass of the entire pharmaceutical composition. The amount of the compound having an amino group in the composition may be, for example, 100 to 1,000 mg per dose, or 200 to 700 mg per dose, in terms of the amount of the component contained in the pharmaceutical composition per daily dose, and the number of doses is 1 to 3 times per day. When the pharmaceutical composition of the present invention uses tranexamic acid, which is also an anti-inflammatory component described below, the content ratio of loxoprofen sodium or a salt thereof to tranexamic acid is not particularly limited as long as it does not affect the effects of the present invention, but the content ratio of tranexamic acid per 1% by mass of loxoprofen sodium dihydrate may be 0.1 to 20% by mass, preferably 0.1 to 10% by mass, and more preferably 0.1 to 5% by mass.

[0024] <Herbal medicines (herbal medicine ingredients)> The pharmaceutical composition of the present invention may contain herbal medicines. The herbal medicines used in the present invention are not particularly limited, but include, for example, ephedra, nandina, scutellaria, onion root, licorice, platycodon, rhizome, rhizome, garlic root, Senega, Fritillaria, fennel, Phellodendron bark, Coptis orb, Zedoary, chamomile, cinnamon bark, gentian, bezoar, animal gall (including yutan), rhizome, ginger, atractylodes, clove, tangerine peel, Atractylodes rhizome, sage, ginseng, Mallotus japonicus, Epilobium chinense, Corydalis chinense, Scutellaria root, rhizome, valerian, calonin, apricot kernel, lycium bark, lycium sieboldii, kaempferia sinensis, gentian root, lycium bark, kaempferia sinensis, geranium, One or more ingredients selected from herbal medicines such as Magnolia officinalis, Gomokushi, Saishin, Zanthoxylum piperitum, Aster rhizome, Zithium rhizome, Peony root, Musk, Xanthomonas rhizome, Cnidium rhizome, Zenko, Swertia japonica, Sophora rhizome, Perilla japonica, Taisan, Dong Qi, Ipecac, Bakumondo, Pinellia japonica, Bankouka, Cardamomum rhizome, Byakkoshi, Poria cocos, Moutan pi, Boehme, Rokujo, and Bowie, and their extracts (extracts, tinctures, dried extracts, etc.), may be blended. In the present invention, it is preferable to include at least one of licorice extract, peony extract, and valerian extract. The content ratio of the herbal medicines in the present invention is not particularly limited, but may be, for example, 1 to 80 mass%, 1 to 50 mass%, 1 to 40 mass%, or 1 to 30 mass% based on the mass of the entire composition when each herbal medicine is an extract.

[0025] The herbal medicines used in the present invention, such as licorice, peony, and valerian, have been used medicinally since ancient times as single ingredients or as traditional Chinese medicines. Herbal powders or extracts obtained according to conventional methods can be used as they are. The herbal powders or extracts can be in the form of ordinary commercially available products or processed products thereof. For example, dried, chopped, processed products can be further pulverized into a fine powder (fine powder) for use as a dry powder. The form of the extract from the herbal medicine is not particularly limited, and any form, such as a dried extract, extract powder, soft extract, liquid extract, or tincture containing ethanol or ethanol and water, can be used. Preferred herbal medicines include extracts that offer a high degree of formulation flexibility, such as soft extracts and dried extract powders.

[0026] The extract can be obtained by conventional methods, for example, by extracting the active ingredients having antibacterial activity from the herbal medicine using an extraction solvent. The extraction solvent is often water, a hydrophilic solvent, or a mixture thereof. Examples of the hydrophilic solvent include alcohols such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, s-butanol, and t-butanol; cellosolves such as methyl cellosolve and ethyl cellosolve; ketones such as acetone; ethers such as dioxane and tetrahydrofuran; and nitrogen-containing solvents such as pyridine, morpholine, acetonitrile, N,N-dimethylformamide, dimethylacetamide, and N-methylpyrrolidone. These hydrophilic solvents may be used alone or as a mixture of two or more of them. Licorice may be used as a conventional anti-inflammatory agent, cold medicine, antipyretic analgesic, antitussive expectorant, gastrointestinal medicine, anthelmintic, internal medicine for rhinitis, throat freshener, stomachic freshener, vitamin-containing health supplement, sweetener, flavoring agent, colorant, flavoring agent, perfume, or excipient.

[0027] When "licorice" is used in the present invention, it is preferable to use those listed in the 18th edition of the Japanese Pharmacopoeia. Licorice other than those mentioned above is also commercially available and therefore easily available. Commercially available licorice includes, for example, extracts using water or 30% ethanol aqueous solution as an extraction solvent, and various extracts with various crude drug equivalent ratios are sold depending on the type of extract, such as licorice extract, dried licorice extract, soft licorice extract, and liquid licorice extract. In addition to these licorice extracts, licorice extracts, licorice extract solutions, etc. may also be used as appropriate and are not particularly limited. When commercially available licorice is used in a pharmaceutical composition, it is sufficient to use licorice so that the licorice content in the tablet is appropriate, taking into account, for example, the crude drug equivalent ratio.

[0028] The amount of licorice (licorice or licorice extract) contained in the pharmaceutical composition of the present invention is not particularly limited, but the amount of the ingredient contained in the pharmaceutical composition per daily dose, calculated as the amount of the crude drug, is preferably 10 mg to 10 g, more preferably 150 mg to 5 g, and even more preferably 500 mg to 3000 mg, and may be 500 mg to 1500 mg. The number of doses is 1 to 3 times a day.

[0029] In the present invention, for example, when a licorice dry extract is used, the content of the licorice dry extract is not particularly limited, but may be 0.1 to 80% by mass, or 1 to 50% by mass, preferably 5 to 40% by mass, and more preferably 10 to 30% by mass, based on the mass of the entire pharmaceutical composition.

[0030] When "valerian" is used in the present invention, the "valerian" can preferably be one listed in the 18th edition of the Japanese Pharmacopoeia. Valerian other than those mentioned above is also commercially available and can be easily obtained. As commercially available valerian, for example, valerian powder or valerian extract (e.g., soft extract, dry extract, etc.) can be used, and is not particularly limited. When commercially available valerian is used in a pharmaceutical composition, it is sufficient to use valerian so that the valerian content in the tablet is appropriate, taking into account the crude drug conversion ratio.

[0031] When "valerian (valerian or valerian extract)" is used in the present invention, the content is not particularly limited, but for example, the amount of the ingredient contained in a tablet per daily dose, converted into the amount of the original herbal drug, may be 1 to 6,000 mg, preferably 10 to 2,000 mg, more preferably 20 to 1,440 mg, even more preferably 60 mg to 1,000 mg, or may be 60 to 450 mg, and the number of administrations is 1 to 3 times a day.

[0032] In the present invention, for example, when valerian extract is used, the content of the valerian extract is not particularly limited, but may be 1 to 50% by mass, preferably 2 to 40% by mass, and more preferably 3 to 20% by mass, based on the mass of the entire pharmaceutical composition.

[0033] When "peony" is used in the present invention, it is preferable to use one listed in the 18th revised Japanese Pharmacopoeia. Peony other than those mentioned above is also commercially available and can be easily obtained. Examples of commercially available peony include peony powder and peony extract (including, for example, dried extract and soft extract), and are not particularly limited. When using commercially available peony in a pharmaceutical composition, it is sufficient to use peony so that the peony content in the tablet is appropriate, taking into account the crude drug equivalent ratio.

[0034] When "peony (peony or extract thereof)" is used in the present invention, the content is not particularly limited, but is preferably administered in an amount of 100 to 5000 mg, more preferably 150 to 2000 mg, and particularly preferably 200 to 900 mg per day in terms of the crude drug content of peony, and the number of administrations is 1 to 3 times per day.

[0035] In the present invention, for example, when peony dry extract is used, the content ratio of the peony dry extract is not particularly limited, but may be 1 to 50 mass %, preferably 2 to 40 mass %, and more preferably 3 to 20 mass %, based on the mass of the entire pharmaceutical composition.

[0036] The pharmaceutical composition of the present invention can be formulated according to a conventional method. In the present invention, for example, tablets may be produced by preparing granules containing loxoprofen or a salt thereof and a crude drug selected from the group consisting of (B-1) to (B-7), adding a powder component to the obtained granules so as to form an outer granule portion, and compressing the mixture.

[0037] That is, the tablets can be produced by, for example, the steps of producing granules (at least one granule) containing loxoprofen or a salt thereof and a herbal medicine selected from the group consisting of (B-1) to (B-7); and mixing the granules with desired additives (powders) and compressing the mixture to produce tablets. Alternatively, loxoprofen or a salt thereof and the herbal medicine selected from the group consisting of (B-1) to (B-7) may each be contained in separate granules, and the ingredients placed outside the granules may optionally be in the form of granules.

[0038] The final component (external part of granulated granules) in the present invention is a part that constitutes the exterior of the granulated granules in the tablet. For example, it may be a part that covers one granulated granule in the tablet, or a part that covers multiple granulated granules. It may also be a part that covers at least one granulated granule in the tablet and constitutes the outer surface of the tablet. The tablet may have granulated granules therein, and the granulated granules may contain loxoprofen or a salt thereof and a herbal medicine selected from the group consisting of (B-1) to (B-7).

[0039] The formulation can be prepared using known methods and additives as appropriate, provided that the additives do not impair the effects of the present invention.

[0040] Examples of additives include pharmaceutically acceptable carriers such as excipients, binders, disintegrants, disintegration aids, lubricants, fluidizing agents, glossing agents, foaming agents, moisture-proofing agents, surfactants, stabilizers, emulsifiers, antioxidants, fillers, preservatives, sweeteners, flavoring agents, refreshing agents, flavors, fragrances, colorants, base materials, coating agents, sugar-coating agents, plasticizers, dispersants, and antifoaming agents. Conventionally known formulation additives that can be used in pharmaceutical compositions can be used for the above-mentioned purposes.

[0041] Examples of excipients include candy powder, gum arabic, powdered gum arabic, cocoa butter, caramel, sodium carboxymethyl starch, hydrated silicon dioxide, anhydrous amorphous silicon oxide, xylitol, magnesium aluminosilicate, calcium silicate, magnesium silicate, light anhydrous silicic acid, anhydrous calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate granules, calcium monohydrogen phosphate, calcium hydrogen phosphate hydrate, calcium hydrogen phosphate granules, sodium hydrogen phosphate hydrate, calcium dihydrogen phosphate hydrate, sodium dihydrogen phosphate hydrate, potassium dihydrogen phosphate, crystalline cellulose, crystalline cellulose-carmellose sodium, crystalline cellulose (fine particles), crystalline cellulose (granules), powdered cellulose, synthetic aluminum silicate, synthetic aluminum silicate-hydroxypropyl starch-crystalline cellulose, wheat starch, rice flour, rice starch, heavy anhydrous silicic acid, refined sucrose, refined sucrose spherical granules, gelatin, D-sorbitol, calcium carbonate, magnesium carbonate, precipitated calcium carbonate, low-substituted hydroxypropyl cellulose , dextrin, corn starch, corn starch granules, trehalose, silicon dioxide, lactose hydrate, lactose granules, sucrose, potato starch, hydroxypropyl starch, partially pregelatinized starch, powdered sugar, powdered candy, powdered reduced maltose syrup, powdered cellulose, pectin, polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 60, maltitol, D-mannitol, calcium sulfate, erythritol, glucose, fructose, etc.

[0042] The binder may be one or more components selected from gum arabic, powdered gum arabic, dried plum powder, gelatin, shellac, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyvinyl alcohol (fully saponified), polyvinyl alcohol (partially saponified), methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, butyl methacrylate-methyl methacrylate copolymer, methyl cellulose, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, and the like.

[0043] Examples of disintegrants include carboxymethyl starch sodium, carmellose, carmellose calcium, croscarmellose sodium, croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, hydroxypropyl starch, partially pregelatinized starch, and the like.

[0044] Examples of disintegration aids include carboxymethyl starch sodium, carmellose, carmellose calcium, croscarmellose sodium, light anhydrous silicic acid, crystalline cellulose, sodium bicarbonate, precipitated calcium carbonate, lactose hydrate, hydroxypropyl starch, polysorbate 40, polysorbate 60, polysorbate 80, macrogol 1500, macrogol 4000, and the like.

[0045] Examples of lubricants include magnesium stearate, calcium stearate, talc, sucrose fatty acid esters, glycerin fatty acid esters, polyethylene glycol, hydrogenated oil, and sodium stearyl fumarate.

[0046] The fluidizing agent may be one or more components selected from the group consisting of hydrous silicon dioxide, light anhydrous silicic acid, synthetic aluminum silicate, heavy anhydrous silicic acid, magnesium alumina hydroxide, stearic acid, calcium stearate, magnesium stearate, tricalcium phosphate, talc, calcium hydrogen phosphate granules, and the like.

[0047] The glossing agent may be, for example, one or more components selected from carnauba wax, white beeswax, purified shellac, Macrogol 400, Macrogol 1500, Macrogol 4000, Macrogol 6000, Macrogol 6000NF, beeswax, etc.

[0048] As the foaming agent, for example, one or more components selected from dry sodium carbonate, tartaric acid, potassium hydrogen tartrate, sodium hydrogen carbonate, anhydrous citric acid, etc. may be blended.

[0049] The moisture-proofing agent may be one or more components selected from the group consisting of ethyl cellulose, olive oil, dried aluminum hydroxide gel, glycerin, magnesium silicate, light anhydrous silicic acid, hardened oil, synthetic aluminum silicate, sucrose fatty acid ester, stearic acid, magnesium stearate, purified shellac, purified sucrose, talc, neutral anhydrous sodium sulfate, precipitated calcium carbonate, a mixture of fumaric acid, stearic acid, polyvinyl acetal diethylaminoacetate, and hydroxypropyl methylcellulose 2910, and polyvinyl acetal diethylaminoacetate.

[0050] The surfactant may be one or more components selected from, for example, sucrose fatty acid esters, polyoxyethylene hydrogenated castor oil 20, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan beeswax, polyoxyethylene nonylphenyl ether, polyoxyethylene (20) polyoxypropylene (20) glycol, polyoxyethylene (105) polyoxypropylene (5) glycol, polyoxyethylene (120) polyoxypropylene (40) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (10) polyoxypropylene (4) cetyl ether, polysorbate 20, polysorbate 60, polysorbate 80, macrogol 400, sorbitan monooleate, glycerin monostearate, sorbitan monostearate, sorbitan monolaurate, sodium lauryl sulfate, and the like.

[0051] Examples of stabilizers include adipic acid, L-aspartic acid, sodium L-aspartate, DL-alanine, L-alanine, L-arginine, L-arginine hydrochloride, sodium alginate, propylene glycol alginate, benzoic acid, sodium benzoate, ethylenediamine, calcium disodium edetate, sodium edetate, tetrasodium edetate, tetrasodium edetate tetrahydrate, zinc chloride, ammonium chloride, calcium chloride hydrate, cetylpyridinium chloride, ferric chloride, sodium chloride, magnesium chloride, and calcium chloride. Stain, L-histidine hydrochloride, cocoa butter, carboxyvinyl polymer, carmellose calcium, carmellose sodium, hydrated silicon dioxide, dried sodium carbonate, glycine, glycerin, glycerin fatty acid ester, calcium gluconate hydrate, sodium gluconate, magnesium gluconate, potassium L-glutamate, sodium L-glutamate, L-lysine glutamate, light anhydrous silicic acid, crystalline sodium dihydrogen phosphate, sodium chondroitin sulfate, zinc oxide, L-cystine, L-cysteine, tartaric acid, sucrose fatty acid ester Stearic acid, refined gelatin, refined soy lecithin, gelatin, gelatin hydrolysate, sorbitan fatty acid ester, taurine, talc, calcium carbonate, potassium bicarbonate, sodium bicarbonate, sodium carbonate hydrate, magnesium carbonate, natural vitamin E, tocopherol, tocopherol acetate, lactose, concentrated glycerin, povidone, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether, polyoxyethylene nonylphenyl ether, polyoxyethylene hydrogenated castor oil, poly Polyoxyethylene (42) polyoxypropylene (67) glycol, polyoxyethylene (54) polyoxypropylene (39) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (196) polyoxypropylene (67) glycol, polyoxyethylene coconut oil fat glyceryl (7E.O.), polysorbate 20, polysorbate 60, polysorbate 80, polyvinyl alcohol (partially saponified), macrogol 300, macrogol 400, macrogol 4000, anhydrous citric acid,One or more ingredients selected from anhydrous sodium citrate, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, methylcellulose, l-menthol, glycerin monostearate, medicinal charcoal, magnesium sulfate hydrate, DL-malic acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, calcium dihydrogen phosphate hydrate, L-leucine, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, etc. may be blended.

[0052] Examples of emulsifiers include glycerin fatty acid esters, propylene glycol fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyglycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyethylene glycol fatty acid esters, and hydrogenated soybean phospholipids.

[0053] Examples of antioxidants include ascorbic acid, L-ascorbic acid stearate, citric acid hydrate, soybean lecithin, natural vitamin E, natural vitamin E, tocopherol, tocopherol acetate, ascorbic acid palmitate, and sodium pyrosulfite.

[0054] Examples of fillers include RSS No. 1 raw rubber, starch acrylate 1000, hydrous silicon dioxide, titanium oxide, silicon dioxide, and calcium hydrogen phosphate.

[0055] Examples of preservatives include benzoic acid, sodium benzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, methyl parahydroxybenzoate, dehydroacetic acid, sodium dehydroacetate, sorbic acid, and phenoxyethanol.

[0056] The sweetener may be one or more components selected from, for example, aspartame, acesulfame potassium, hydrangea, hydrangea powder, reduced maltose syrup, licorice, licorice extract, licorice powder, xylitol, dipotassium glycyrrhizinate, disodium glycyrrhizinate, saccharin, saccharin sodium hydrate, sucralose, stevia extract, purified stevia extract, refined sucrose, fructose, sucrose, maltitol, D-mannitol, erythritol, and the like.

[0057] The flavoring agent may be one or more ingredients selected from sodium chloride, orange, orange oil, cacao powder, fructose, caramel, xylitol, calcium citrate, citric acid hydrate, sodium citrate hydrate, L-glutamic acid, sodium L-glutamate, grapefruit extract, brown sugar, saccharin, saccharin sodium hydrate, tartaric acid, D-tartaric acid, potassium hydrogen tartrate, DL-sodium tartrate, sucralose, stevia extract, purified stevia extract, Swertia japonica, D-sorbitol, tannic acid, trehalose hydrate, fructooligosaccharide, powdered sugar, peppermint powder, D-mannitol, dl-menthol, l-menthol, menthol powder, green tea powder, DL-malic acid, sodium DL-malate, lemon oil, rose oil, and the like.

[0058] Examples of the cooling agent include fennel oil, d-camphor, dl-camphor, cinnamon oil, peppermint water, peppermint oil, and l-menthol.

[0059] As the flavoring, for example, one or more components selected from orange flavor, guarana extract, sweet orange, strawberry, brown sugar flavor, strawberry flavor, cherry flavor, banana powder flavor, peach essence, fruit essence, peppermint, melon powder flavor, 1-menthol, peppermint oil, etc. can be blended.

[0060] Examples of fragrances include fennel powder, fennel oil, ethyl vanillin, d-camphor, dl-camphor, spearmint oil, turpentine, pineapple powder flavor 51357, pineapple powder flavor 59492, peppermint water, peppermint oil, vanilla powder flavor 54286, vanillin, bergamot oil, d-borneol, dl-borneol, dl-menthol, l-menthol, eucalyptus oil, rose water, and rose oil.

[0061] Examples of colorants that can be blended include one or more components selected from yellow iron oxide, yellow ferric oxide, orange essence, brown iron oxide, carbon black, caramel, β-carotene, gold leaf, black iron oxide, titanium oxide, ferric oxide, dizazo yellow, Food Blue No. 1, Food Yellow No. 4, Food Yellow No. 5, Food Blue No. 2 Aluminum Lake, Food Yellow No. 4 Aluminum Lake, Food Red No. 2, Food Red No. 3, Food Red No. 102, ferric oxide / glycerin suspension, copper chlorophyllin sodium, copper chlorophyll, phenol red, malachite green, methylene blue, medicinal charcoal, riboflavin, riboflavin butyrate, riboflavin sodium phosphate, green tea powder, and rose oil.

[0062] The bases include gum arabic powder, pregelatinized starch, ethyl cellulose, cacao butter, carnauba wax, carboxyvinyl polymer, carmellose, carmellose sodium, reduced maltose syrup, hydrated silicon dioxide, dried aluminum hydroxide gel, agar, agar powder, xanthan gum, glycine, glycerin, glycerin fatty acid ester, light anhydrous silicic acid, crystalline cellulose, hardened oil, synthetic aluminum silicate, synthetic magnesium sodium silicate, titanium oxide, tartaric acid, sucrose fatty acid ester, silicone oil, stearic acid, magnesium stearate, gelatin, D-sorbitol, talc, calcium carbonate, corn starch, lactic acid, ethyl lactate, calcium lactate hydrate, lactic acid-glycolic acid copolymer, concentrated glycerin, potato starch, and hydroxypropyl cellulose. The composition may contain one or more ingredients selected from the group consisting of cellulose, hypromellose, pullulan, pectin, povidone, polysorbate 60, polysorbate 80, polyvinyl alcohol (partially saponified), microcrystalline wax, macrogol 200, macrogol 300, macrogol 400, macrogol 1000, macrogol 1500, macrogol 1540, macrogol 4000, macrogol 6000, macrogol 6000NF, macrogol 20000, D-mannitol, glycerin monostearate, sorbitan monostearate, batyl monostearate, propylene glycol monostearate, polyethylene glycol monostearate, sodium lauryl sulfate, and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.

[0063] Examples of coating agents include ethyl acrylate-methyl methacrylate copolymer dispersion, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate copolymer RS, gum arabic, gum arabic powder, ethyl cellulose, ethyl cellulose aqueous dispersion, carnauba wax, carboxyvinyl polymer, gold leaf, silver leaf, triethyl citrate, glycerin, glycerin fatty acid ester, hardened oil, titanium oxide, sucrose fatty acid ester, stearyl alcohol, stearic acid, magnesium stearate, purified gelatin, purified shellac, gelatin, D-sorbitol, talc, calcium carbonate, magnesium carbonate, medium gold leaf, precipitated calcium carbonate, concentrated glycerin, white shellac, hydroxypropyl cellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose 2910-titanium oxide-macrogol 400 mixture, hypromellose, fumaric acid-stearic acid-polyvinyl acetal diethylamino Examples of the acrylic acid copolymer include methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, methyl acrylate-methacrylic acid-methyl methacrylate copolymer, methylcellulose, 2-methyl-5-vinylpyridine methylacrylate-methacrylic acid copolymer, aluminum monostearate, glycerin monostearate, sorbitan monostearate, sorbitan monolaurate, calcium sulfate, and polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.

[0064] Examples of sugar-coating agents that can be blended include one or more components selected from gum arabic, powdered gum arabic, ethyl cellulose, carnauba wax, carmellose sodium, titanium oxide, stearic acid, polyoxyl 40 stearate, purified gelatin, purified shellac, purified sucrose, gelatin, shellac, talc, precipitated calcium carbonate, white shellac, sucrose, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyvinyl alcohol (partially saponified), macrogol 1500, macrogol 4000, macrogol 6000, macrogol 6000NF, calcium hydrogen phosphate hydrate, calcium dihydrogen phosphate hydrate, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, and the like.

[0065] Examples of the plasticizer that can be blended include one or more components selected from triethyl citrate, glycerin, glycerin fatty acid esters, D-sorbitol, medium-chain fatty acid triglycerides, triacetin, concentrated glycerin, castor oil, polyoxyethylene hydrogenated castor oil 60, propylene glycol, polyoxyethylene (105) polyoxypropylene (5) glycol, polysorbate 80, macrogol 400, macrogol 600, macrogol 1500, macrogol 4000, macrogol 6000, macrogol 6000 NF, glycerin monostearate, isopropyl linoleate, and liquid paraffin.

[0066] Dispersants include aminoalkyl methacrylate polymer RS, gum arabic, powdered gum arabic, carboxyvinyl polymer, sodium carboxymethyl starch, powdered agar, citric acid hydrate, sodium citrate hydrate, glycerin, glycerin fatty acid ester, magnesium silicate, light aluminum oxide, light anhydrous silicic acid, crystalline cellulose, titanium oxide, sucrose fatty acid ester, stearic acid, magnesium stearate, D-sorbitol, soybean lecithin, and low-substituted hydroxypropyl cellulose. , dextrin, corn starch, lactose hydrate, concentrated glycerin, potato starch, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, povidone, polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, polysorbate 20, polysorbate 60, polysorbate 80, microcrystalline wax, macrogol 300, macrogol 4000, macrogol 6000, macrogol 6000NF, anhydrous sodium citrate, methylcellulose, glycerin monooleate, sorbitan monooleate, aluminum monostearate, glycerin monostearate, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, sodium lauryl sulfate, and the like can be blended.

[0067] The antifoaming agent may be one or more components selected from ethanol, glycerin fatty acid ester, dimethylpolysiloxane (for internal use), dimethylpolysiloxane / silicon dioxide mixture, sucrose fatty acid ester, silicone antifoaming agent, silicone oil, sorbitan fatty acid ester, polysorbate 80, etc.

[0068] These additives are not limited to those listed above, and one of these may be used alone or two or more of them may be used in combination.

[0069] The pharmaceutical composition of the present invention can be suitably used for the purpose of suppressing fever, pain, and inflammation. The pharmaceutical composition of the present invention is preferably an anti-inflammatory composition. The active ingredient, loxoprofen or a salt thereof, has antipyretic, analgesic, and anti-inflammatory effects, and is therefore suitably used as an antipyretic analgesic, particularly for the pain relief of headache, menstrual pain (period pain), toothache, pain after tooth extraction, sore throat, lower back pain, joint pain, muscle pain, stiff shoulders, earache, bruise pain, fracture pain, sprain pain, and trauma pain, and for the fever reduction associated with chills and fever. It can also be suitably used as a cold remedy for the relief of cold symptoms (runny nose, stuffy nose, cough, phlegm, sore throat, fever, chills, headache, sneezing, joint pain, and muscle pain).

[0070] The pharmaceutical composition of the present invention can be in a dosage form described in the General Provisions for Preparations of the Japanese Pharmacopoeia, 18th Edition, etc., such as a preparation for oral administration (including tablets, orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, dissolving tablets, etc.) and a preparation for oral application (including oral tablets, troches, sublingual tablets, buccal tablets, adhesive tablets, gums, etc.). The pharmaceutical composition is preferably a solid preparation. The pharmaceutical composition is preferably an oral pharmaceutical composition.

[0071] The solid preparation is preferably a tablet, powder, fine granule, granule, capsule, or pill as described in the Japanese Pharmacopoeia, 18th Edition, more preferably a granule or tablet, and most preferably a tablet. Furthermore, when a granule is subjected to a particle size test according to the Japanese Pharmacopoeia, 18th Edition, a granule that passes entirely through a No. 18 (850 μm) sieve and retains 10% or less of the total amount on a No. 30 (500 μm) sieve is sometimes referred to as a fine granule.

[0072] Granules or tablets may be prepared by coating the preparation with a water-soluble polymer, etc. Examples include film-coated granules and film-coated tablets. Solid preparations may also be sugar-coated.

[0073] When the solid preparation is a tablet, it can be a single-layer tablet or a multi-layer tablet made by compressing two or more layers of powders or granules of different compositions. When the tablet is a multi-layer tablet, loxoprofen or a salt thereof and the specified herbal medicine may be in the same layer or in different layers.

[0074] The pharmaceutical composition of the present invention may further contain other active ingredients, such as antipyretic analgesics, antitussives / expectorants, antihistamines, anti-inflammatory agents, anticholinergic agents, other vitamins, and xanthine derivatives, as needed, within the scope of the present invention. If there are any contraindications for these ingredients, the composition may be formulated by dividing the ingredients into granules or the like.

[0075] The antipyretic analgesic may contain one or more ingredients selected from aspirin, aspirin aluminum, acetaminophen, ethenzamide, sazapirin, salicylamide, lactylphenetidine, ibuprofen, isopropylantipyrine, prazolophen, diclofenac sodium, mefenamic acid, indomethacin farnesyl, acemetacin, etodolac, naproxen, meloxicam, celecoxib, sodium salicylate, and tiaramide hydrochloride.

[0076] Examples of antitussives / expectorants include codeine, codeine phosphate hydrate, dihydrocodeine, dihydrocodeine phosphate, dibunate sodium, dimemorfan phosphate, tipepidine citrate, tipepidine hibenzate, dextromethorphan, dextromethorphan hydrobromide hydrate, dextromethorphan phenolphthalin salt, alloclamide hydrochloride, cloperastine hydrochloride, cloperastine fendizoate, pentoxyverine citrate, and nosca pine, noscapine hydrochloride, trimetoquinol hydrochloride, phenylephrine hydrochloride, pseudoephedrine hydrochloride, pseudoephedrine sulfate, l-methylephedrine hydrochloride, dl-methylephedrine hydrochloride, dl-methylephedrine saccharin salt, guaifenesin, potassium guaiacolsulfonate, potassium cresolsulfonate, L-carbocysteine, ambroxol hydrochloride, bromhexine hydrochloride, L-ethylcysteine ​​hydrochloride, and the like.

[0077] Examples of antihistamines include azelastine hydrochloride, alimemazine tartrate, ebastine, epinastine hydrochloride, emedastine fumarate, oxatomide, olopatadine hydrochloride, carbinoxamine, clemastine fumarate, diphenyl disulfonate, carbinoxamine maleate, d-chlorpheniramine maleate, dl-chlorpheniramine maleate, ketotifen fumarate, diphenylpyraline hydrochloride, diphenylpyraline teoclate, difenyl pyraline hydrochloride, diphenyl pyraline teoclate ... Examples of such antihistamines include phenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine tannate, triprolidine hydrochloride, tripelennamine hydrochloride, thonzylamine hydrochloride, fexofenadine, fenethazine hydrochloride, promethazine hydrochloride, promethazine, mequitazine, methdilazine hydrochloride, loratadine, isopentyl hydrochloride, diphenthenol hydrochloride, methdilazine hydrochloride, mebhydrozine napadisilate, promethazine methylenedisalicylate, and diphenthenol phosphate.

[0078] Anti-inflammatory agents include glycyrrhizinic acid and its derivatives and salts thereof (for example, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, etc.), tranexamic acid, etc.

[0079] Anticholinergic agents include scopolamine hydrobromide, Datura extract, methylscopolamine bromide, methyl-l-hyoscyamine bromide, pirenzepine hydrochloride, butylscopolamine bromide, belladonna alkaloids, belladonna extract, belladonna total alkaloids, isopropamide iodide, diphenylpiperidinomethyldioxolane iodide, Scopolia root extract, Scopolia root total alkaloid citrate, and the like.

[0080] Examples of vitamins include vitamin A, vitamin C, vitamin B1, vitamin B2, vitamin B5, vitamin B6, vitamin B12, vitamin P, vitamin E, hesperidin, nicotinic acid, nicotinamide, panthenol, calcium pantothenate, sodium pantothenate, biotin, a mixture of equal parts of potassium and magnesium aspartate, inositol hexanicotinate, ursodeoxycholic acid, L-cysteine, L-cysteine ​​hydrochloride, orotin, gamma oryzanol, calcium glycerophosphate, calcium gluconate, gluconolactone, glucuronic acid amide, sodium chondroitin sulfate, carrot, coix seed, and iodine. Examples of xanthine derivatives other than the above-mentioned caffeine (other xanthine derivatives) include theophylline and theobromine.

[0081] Examples of vitamins include vitamin B1 and derivatives thereof, such as thiamine, thiamine chloride hydrochloride, thiamine nitrate, dicethiamine hydrochloride, setotiamine hydrochloride, fursultiamine, fursultiamine hydrochloride, octotiamine, shikotiamine, thiamine disulfide, bis-ibutiamine, bis-bentiamine, prosultiamine, and benfotiamine, and salts thereof; vitamin B2 and derivatives thereof, such as riboflavin, riboflavin phosphate, riboflavin butyrate, and riboflavin sodium phosphate, and salts thereof; pantothenic acid, panthenol, pantethine, pantothenic acid, panthenol ... One or more ingredients selected from the group consisting of vitamin B5 and its derivatives and salts such as calcium pantothenate and sodium pantothenate; vitamin B6 and its derivatives and salts such as pyridoxine hydrochloride and pyridoxal phosphate; vitamin B12 and its derivatives and salts such as cyanocobalamin and mecobalamin; vitamin C and its derivatives and salts such as ascorbic acid, sodium ascorbate and calcium ascorbate; and hesperidin and its derivatives and salts.

[0082] These additives are not limited to those listed above, and one of these may be used alone or two or more of them may be used in combination.

[0083] The pharmaceutical composition of the present invention may be temporarily packaged in SP packaging, PTP packaging, stick packaging, bottle packaging, etc., and then stored airtight. These may also be pillow-packaged, and stored in a box, etc. In other words, a pharmaceutical according to one embodiment of the present invention may comprise a pharmaceutical composition and a packaging material for packaging the pharmaceutical composition. Materials used for SP packaging, PTP packaging, stick packaging, and pillow packaging are not particularly limited, and include, for example, single-layer resin films such as polyvinyl chloride film, polyvinylidene chloride film, polypropylene film, polyethylene terephthalate film, and polyethylene film, multi-layer films combining these resin films, and resin films with aluminum foil attached thereto.

[0084] The packaging material for the pharmaceutical composition of the present invention is preferably, for example, packaging made of a material that is less susceptible to moisture (packaging made of at least one of a moisture-proof material and a gas barrier material). For example, a packaging made of a material that is less susceptible to moisture (moisture-proof material) may be PTP (polypropylene) + polyethylene aluminum pillow packaging (a combination of PTP and polyethylene aluminum pillow packaging). Furthermore, taking into consideration the suppression of an increase in the moisture content of the pharmaceutical composition, the storage stability of the pharmaceutical composition, and the stability of the pharmaceutical composition after opening, PTP packaging (Al-Al packaging) using aluminum on both sides may be used as a packaging made of a material that is less susceptible to moisture (moisture-proof material). If moisture absorption is a concern, a desiccant or the like may be simultaneously stored within the bottle packaging or pillow packaging. Known gas barrier materials may be used and are not particularly limited. For example, a laminate film having a functional barrier layer may be used, which may also serve as the moisture-proof material or may be used in combination with the moisture-proof material. Furthermore, the packaging material for the pharmaceutical composition of the present invention is not particularly limited, and environmentally friendly materials such as recycled plastics, biomass plastics, and biodegradable plastics may be used for part or all of the packaging material, as needed, and environmentally friendly containers and packaging may also be used.

[0085] Second Embodiment In a second embodiment of the present invention, the pharmaceutical composition may be in the form of a liquid. In this embodiment, when the dosage form is a liquid, it may be used as an oral liquid pharmaceutical composition, for example, an oral liquid, an oral liquid, an oral spray (atomized agent), or a mouthwash.

[0086] In this embodiment, the content of at least one selected from the group consisting of loxoprofen, a salt thereof, and a hydrate thereof may be 0.016 to 3.0 W / V % relative to the total amount of the oral liquid pharmaceutical composition, and is preferably 0.05 to 1.5 W / V % relative to the total amount of the oral liquid pharmaceutical composition.

[0087] In this embodiment, in addition to at least one selected from the group consisting of loxoprofen, its salts, and hydrates thereof, the following substances may be contained. In this embodiment, sodium azulene sulfonate may be contained. Sodium azulene sulfonate is known as an agent for preventing and treating inflammatory diseases in the fields of gastrointestinal tract, oral cavity, otorhinolaryngology, ophthalmology, and the like. Sodium azulene sulfonate is a known substance and is readily available on the market. When sodium azulene sulfonate is used, the amount may be 0.02 w / v% to 0.5 w / v%, preferably 0.02 w / v% to 0.4 w / v%, and particularly preferably 0.02 w / v% to 0.1 w / v%, based on the total volume of the liquid. The unit of amount "w / v%" refers to mass-to-volume percentage (the content (g) of the component in 100 mL of the liquid) (the same applies hereinafter to other components).

[0088] In this embodiment, a sugar alcohol may be contained. Examples of sugar alcohols include maltitol, erythritol, xylitol, sorbitol, etc. When a sugar alcohol is used, the content of the sugar alcohol may be 20 w / v % to 40 w / v % relative to the total volume of the liquid, preferably 25 w / v % to 40 w / v %, and particularly preferably 25 w / v % to 35 w / v %.

[0089] In this embodiment, a quaternary ammonium salt may be contained. Examples of quaternary ammonium salts include cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride. One selected from these may be blended alone, or two or more may be blended in combination. The content of the quaternary ammonium salt is 0.05 w / v% to 0.5 w / v%, preferably 0.05 w / v% to 0.3 w / v%, and particularly preferably 0.1 w / v% to 0.3 w / v%, based on the total volume of the liquid.

[0090] The liquid preparation according to this embodiment may contain an alcohol such as a monohydric alcohol or a polyhydric alcohol. Examples of the monohydric alcohol include methanol, ethanol, propanol, isopropanol, butanol, etc., and one selected from these may be used alone or in combination of two or more. Ethanol is particularly preferred. The polyhydric alcohol is preferably one or more selected from glycerin, ethylene glycol, propylene glycol, and butylene glycol. Glycerin is preferred. The alcohol content is not particularly limited, but may be less than 40 w / v% of the total volume of the liquid preparation.

[0091] In this embodiment, the aqueous preparation may contain a pH adjuster. Examples of pH adjusters include citric acid, sodium citrate, lactic acid, sodium lactate, and sodium hydroxide. The pH of the aqueous preparation of the present invention may be adjusted to about 6 to 9, preferably about 7.0 to 8.5, and particularly preferably about 7.0 to 8.0.

[0092] In this embodiment, the water content may be, but is not particularly limited to, 15 to 80%, and preferably 15 to 75%.

[0093] In this embodiment, flavoring agents, buffers, preservatives, stabilizers, and the like that are typically added to pharmaceutical preparations can be added as long as they do not contradict the object of the present invention.

[0094] The flavoring agent has the effect of mitigating the taste specific to the medicinal ingredient; for example, erythritol and L-menthol act as flavoring agents. Suitable examples of buffering agents include buffer solutions such as phosphates, acetates, carbonates, and citrates. Parabens can also be used as preservatives for the aqueous formulation used in the present invention. Examples of stabilizers include surfactants (e.g., polyoxyethylene hydrogenated castor oil, polysorbates, lauromacrogol, macrogol, sodium lauryl sulfate, etc.), sodium edetate, cyclodextrin, sulfites, citric acid or its salts, etc.

[0095] The oral liquid pharmaceutical composition of this embodiment can be prepared by known preparation methods, such as the methods described in the 18th Edition of the Japanese Pharmacopoeia and the General Rules for Preparations for Liquid Preparations. For example, the oral liquid pharmaceutical composition of this embodiment can be prepared by homogeneously physically mixing other additives.

[0096] The oral liquid pharmaceutical composition of this embodiment can be easily prepared by dissolving the above-mentioned ingredients in, for example, distilled water or sterilized purified water. For example, when used as an oral agent, it may be used for oral inflammatory diseases, specifically, for example, throat pain, dry throat, throat swelling, throat discomfort, hoarseness, and stomatitis caused by throat inflammation. For example, when the oral liquid pharmaceutical composition of this embodiment is used for adults, the oral liquid pharmaceutical composition may be filled into a spray-type container and sprayed onto the affected area in an appropriate amount several times a day as a throat spray. The number of doses may be increased or decreased as appropriate depending on the severity of the symptoms.

[0097] Specific dosage forms of the oral liquid pharmaceutical composition in this embodiment include, for example, oral liquids, oral liquids, mouthwashes, and oral sprays (for example, gas-filled aerosol types and pump types may also be used), and these can be produced using appropriate additives and bases suitable for each dosage form in accordance with standard methods described in the 18th Edition of the Japanese Pharmacopoeia, etc.

[0098] The preparation can be housed and sealed in, for example, a glass container or package, a metal container or package such as aluminum, or an olefin resin container or package such as polyethylene or polypropylene, and may further be housed in a moisture-proof bag containing a metal such as aluminum. The container or package may also be made from environmentally friendly raw materials such as recycled plastics or biomass raw materials, and, if necessary, any material may be used that prevents deterioration of the topical skin preparation due to external factors, elements, or environmental changes, such as laminated materials, gas barrier materials, or heat and light in high-temperature environments, and that properly maintains the quality of the topical skin preparation.

[0099] The present invention will be explained in more detail below by way of examples, but the present invention is not limited to these examples in any way.

[0100] <Test Materials> (1) Substances The following substances were used in the experiment: Loxoprofen sodium hydrate (LOX), 10% by weight aqueous acetic acid solution (hereinafter sometimes referred to as AA), physiological saline, and triple anesthetic solution (medetomidine, midazolam, butorphanol).

[0101] <Test Method> <Experiment 1. Preparation of Pharyngitis Model Rat> Figure 1 shows an endoscopic photograph of the pharynx of a pharyngitis model rat. To take an endoscopic photograph of the pharynx of the pharyngitis model rat in Figure 1, the rat was placed on a fixed table, rubber bands were placed around the upper and lower anterior teeth of the rat's jaw to open the mouth, and the rat's position was adjusted so that the epiglottis could be seen through the endoscope. As shown in Figure 1, male Wister rats weighing 300 g to 450 g were used, and under triple anesthesia (50 mg / kg, intraperitoneal administration), 10 μl of a 10% by mass aqueous solution of acetic acid diluted with distilled water was applied to the posterior pharynx wall of the rat using a microapplicator (AA treatment in Figure 1) to induce pharyngitis.

[0102] Experiment 2: Measurement of water swallowing reflex Using the pharyngitis model rats obtained in Experiment 1, the water swallowing reflex latency, the number of swallowing reflexes, and the swallowing reflex time interval were measured as an evaluation of pharyngitis, as shown in Figure 2. The water swallowing reflex was measured using an endoscope under triple anesthesia (50 mg / kg, intraperitoneal administration), and water was administered for 10 seconds at a flow rate of 3 μl / s using a syringe pump through a cannula inserted into the pharynx of the rat. The time until the first reflex occurred (swallowing reflex latency), the number of swallowing reflexes within 10 seconds from the first reflex, and the time interval between each swallowing reflex were measured. Whiteout in the endoscopic image was measured as swallowing. As shown in Figure 2, the following groups were prepared: Group [1] Sham + Veh group (pharyngeal application: distilled water, intraperitoneal administration: saline (Veh)); Group [2] AA10% + Veh group (pharyngeal application: 10% by mass aqueous acetic acid (AA10%), intraperitoneal administration: saline (Veh)); and Group [3] AA10% + Lox group (pharyngeal application: 10% by mass aqueous acetic acid (AA10%), intraperitoneal administration: loxoprofen 4 m / kg). The water swallowing reflex in each group was measured 1 hour after intraperitoneal administration.

[0103] Experiment 3: Histological Analysis: Furthermore, rats were perfused with 4% paraformaldehyde (PFA), and pharyngeal tissue was collected and embedded in paraffin before being stained with hematoxylin and eosin (HE) (see Figure 3). As shown in Figure 3, the thickness of the lamina propria was measured to assess the degree of edema due to inflammation. One day after acetic acid treatment, which resulted in the greatest reduction in the water swallowing reflex, loxoprofen was administered intraperitoneally at 4 mg / kg, and the water swallowing reflex was measured one hour later (see Figures 2 and 3). Physiological saline was administered to the control group (see Figure 2).

[0104] <Experimental Results: Experiments 1 to 3> As shown in Figure 4, the pharyngitis model rats (10% by weight acetic acid aqueous solution administration group, AA group) showed a decrease in water swallowing reflex function, such as an increase in the swallowing reflex interval and a decrease in the number of swallowing reflexes. On the other hand, as shown in Figure 5, the loxoprofen administration group in Experiment 2 showed a significant increase in the swallowing reflex frequency and a decrease in the swallowing reflex time interval one hour after administration compared to the control group. The results in Figure 5 indicate that loxoprofen tends to restore the decrease in water swallowing reflex function caused by pharyngitis. As shown in Figure 6, HE staining in Experiment 3 revealed infiltration of inflammatory cells in both the loxoprofen administration group and the control group, but the loxoprofen administration group showed significantly suppressed swelling of the submucosal layer (lamina propria).

[0105] <Discussion of the Results of Experiments 1-3> Acetic acid treatment damaged the mucosal epithelium of pharyngitis, and inflammation-induced swelling of the lamina propria was observed. It is believed that this damage to the mucosal epithelium and swelling of the lamina propria led to a decrease in water swallowing reflex function (Figure 4). In the loxoprofen-treated group, a trend toward recovery of swallowing frequency and swallowing interval, and suppression of lamina propria swelling was observed (Figures 5 and 6). Six days after acetic acid treatment, the latency of the water swallowing reflex, recovery of swallowing frequency, regeneration of the mucosal epithelium, and suppression of lamina propria swelling were observed over time (Figure 6). These experimental results suggest that recovery of the water swallowing reflex is influenced by [1] recovery of the mucosal epithelium and [2] suppression of lamina propria swelling. Furthermore, these experimental results suggest that loxoprofen contributes particularly to [2] suppression of lamina propria swelling in the recovery of the water swallowing reflex. These results suggest that loxoprofen may restore water swallowing reflex function by suppressing pharyngeal swelling.

[0106] Although the preferred embodiments and examples of the present invention have been described above, the present invention is not limited to these. Additions, omissions, substitutions, and other modifications to the configuration are possible without departing from the spirit of the present invention.

[0107] The pharmaceutical composition of the present invention is suitably used as an antipyretic analgesic, particularly for relieving pain such as headache, menstrual pain (period pain), toothache, pain after tooth extraction, sore throat, lower back pain, joint pain, muscle pain, stiff shoulder pain, earache, pain from bruises, bone fractures, sprains, and pain from trauma, and for reducing fever during chills and fever, and is also suitably used as a cold medicine for relieving various cold symptoms (runny nose, stuffy nose, cough, phlegm, sore throat, fever, chills, headache, sneezing, joint pain, and muscle pain).

Claims

1. A pharmaceutical composition comprising at least one selected from the group consisting of rofecoxib, its salts and hydrates thereof, and having an effect of suppressing pharyngitis.

2. The pharmaceutical composition according to claim 1, which has the effect of restoring water swallowing reflex function.

3. The pharmaceutical composition according to claim 1, which has the effect of suppressing swelling of the lamina propria of the mucosa.

4. The pharmaceutical composition according to claim 1, which has the effect of regenerating mucosal epithelium.

5. The pharmaceutical composition according to claim 1, wherein the content of at least one selected from the group consisting of rofecoxib, its salts, and hydrates thereof in the pharmaceutical composition is 5 to 30% by mass.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the daily dosage of at least one selected from the group consisting of loxoprofen, its salts, and hydrates thereof is 10 to 180 mg in terms of anhydrous amount.

7. The pharmaceutical composition according to any one of claims 1 to 5, which is in the form of a solid preparation or a liquid preparation.

8. The pharmaceutical composition according to any one of claims 1 to 5, which is in the form of an oral liquid, an oral liquid, an oral spray, or a mouthwash.

9. The pharmaceutical composition according to any one of claims 1 to 5, which is an oral pharmaceutical composition.

10. The pharmaceutical composition according to any one of claims 1 to 5, further comprising at least one selected from the group consisting of antacids, caffeines, sedatives, herbal medicines, antitussives / expectorants, antihistamines, anti-inflammatory agents, anticholinergic agents, and vitamins.

11. The pharmaceutical composition according to any one of claims 1 to 5, which is used as an antipyretic analgesic or cold remedy.

12. The pharmaceutical composition according to claim 7, wherein the dosage form is a solid formulation, and the dosage form of the solid formulation is a tablet, fine granules, granules or capsule.

Citation Information

Patent Citations

  • Composition for oral administration

    JP2001010977A